Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.29
+21.8%
$3.57
$3.96
$12.00
$5.90M1.557,305 shs93,792 shs
Mallinckrodt plc stock logo
MNK
Mallinckrodt
$0.34
$0.75
$6.42
$1.58MN/A2.62 million shs39,227 shs
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
$0.65
+1.7%
$0.66
$2.08
$4.41
$5.60M-0.2639,605 shs84,345 shs
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$8.20
-3.5%
$7.11
$0.06
$0.61
$4.61M2.43802,052 shs5,615 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
+21.79%+15.38%-20.76%-7.37%-43.98%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00%0.00%0.00%0.00%0.00%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
+1.72%+1.56%-7.14%-17.70%-82.76%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-3.53%-8.99%-10.38%+73.54%-77.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.3315 of 5 stars
3.03.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00
N/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00
N/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
0.00
N/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.00
Hold$131.251,500.61% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$2.37M2.48N/AN/A$14.99 per share0.22
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/A$47.48 per shareN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/A$1.50 per shareN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$4.91M0.94N/AN/A$1.88 per share4.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$14.86N/AN/A-760.32%-83.45%-45.76%N/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%11/5/2025 (Estimated)
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$47.92M-$99.25N/AN/AN/A-555.23%-62.10%-47.49%11/10/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
5.94
5.93
Mallinckrodt plc stock logo
MNK
Mallinckrodt
1.18
0.57
0.31
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/A
2.41
2.41
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.01
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
83.74%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
1.37%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%

Insider Ownership

CompanyInsider Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.10%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.30%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
1.05%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
201.79 million1.79 millionNo Data
Mallinckrodt plc stock logo
MNK
Mallinckrodt
2,70013.17 million13.13 millionNot Optionable
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
108.62 million8.53 millionNot Optionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
20562,00037.54 millionOptionable

Recent News About These Companies

Comparing Spruce Biosciences (NASDAQ:SPRB) & Zomedica (OTC:ZOMDF)
Spruce Biosciences Announces Reverse Stock Split
SPRB Spruce Biosciences, Inc. - Seeking Alpha
Spruce Biosciences Inc Ordinary Shares
Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeterna Zentaris stock logo

Aeterna Zentaris NASDAQ:AEZS

$3.29 +0.59 (+21.79%)
As of 08/22/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Mallinckrodt stock logo

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

NeuroBo Pharmaceuticals stock logo

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.65 +0.01 (+1.72%)
As of 08/22/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Spruce Biosciences stock logo

Spruce Biosciences NASDAQ:SPRB

$8.20 -0.30 (-3.53%)
As of 08/22/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.